长春高新：注射用GenSci143临床试验申请获受理

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. ("Jinsai Pharmaceutical"), has received written notification from the U.S. Food and Drug Administration (FDA) that the clinical trial application for its injectable GenSci143 has been accepted, targeting advanced solid tumors [1] Group 1 - The clinical trial application for GenSci143 has been accepted by the FDA [1] - The indication for GenSci143 is advanced solid tumors [1]